The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
Official Title: Efficacy of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients With Compensated Cirrhosis and Low Viral Load: a Multicenter, Prospective Study
Study ID: NCT04646928
Brief Summary: To analyze the incidence of liver cancer after entecavir administration among patients with low viral load and cirrhosis due to chronic hepatitis B infection.
Detailed Description: To analyze the incidence of liver cancer after entecavir administration among patients with low viral load (HBV DNA titer\<2,000 IU/mL (104 copies/mL)) and cirrhosis due to chronic hepatitis B infection.
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Soon Chun Hyang University Hospital Bucheon, Bucheon, , Korea, Republic of
Soon Chun Hyang University Hospital Cheonan, Cheonan, , Korea, Republic of
Bundang Jesaeng Hospital, Gyeonggi-do, , Korea, Republic of
Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do, , Korea, Republic of
CHA Bundang Medical Center, Gyeonggi-do, , Korea, Republic of
Seoul National University Bundang Hospital, Gyeonggi-do, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Ajou University Hospital, Suwon, , Korea, Republic of
The Catholic University of Korea, St. Vincent's Hospital, Suwon, , Korea, Republic of
Gachon University, Donginchoen Gil Hospital, Sŏngnam, , Korea, Republic of
Name: SungKyu Hwang, MD
Affiliation: Principal Investigator
Role: PRINCIPAL_INVESTIGATOR